• Title of article

    Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

  • Author/Authors

    Peter G?de، نويسنده , , Pernille Vedel، نويسنده , , Hans-Henrik Parving، نويسنده , , Oluf Pedersen، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1999
  • Pages
    6
  • From page
    617
  • To page
    622
  • Abstract
    Background In type 2 diabetes mellitus the aetiology of long-term complications is multifactorial. We carried out a randomised trial of stepwise intensive treatment or standard treatment of risk factors in patients with microalbuminuria. Methods In this open, parallel trial patients were allocated standard treatment (n=80) or intensive treatment (n=80). Standard treatment followed Danish guidelines. Intensive treatment was a stepwise implementation of behaviour modification, pharmacological therapy targeting hyper-glycaemia, hypertension, dyslipidaemia, and microalbuminuria. The primary endpoint was the development of nephropathy (median albumin excretion rate >300 mg per 24 h in at least one of the two-yearly examinations). Secondary endpoints were the incidence or progression of diabetic retinopathy and neuropathy. Findings The mean age was 55·1 years (SD 7·2) and patients were followed up for 3·8 years (0·3). Patients in the intensive group had significantly lower rates of progression to nephropathy (odds ratio 0·27 [95% CI 0·10–0·75]), progression of retinopathy (0·45 [0·21–0·95]), and progression of autonomic neuropathy (0·32 [0·12–0·78]) than those in the standard group. Interpretation Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy. However, further studies are needed to establish the effect of intensified multifactorial treatment on macrovascular complications and mortality.
  • Journal title
    The Lancet
  • Serial Year
    1999
  • Journal title
    The Lancet
  • Record number

    579601